{"filings":[{"id":13964,"accession_number":"0001193125-26-216921","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2026-05-11T20:32:28+00:00","items":["8.01","9.01"],"status":"ready","headline":"Scilex declares dividend of Dream Bowl Meme Coin I tokens; 5 tokens per share; payment begins May 26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date Apr 30, 2026; holders of common, certain warrants, convertible notes, Series A preferred eligible.","Each share of common (or equivalent) receives 5 Dream Bowl Tokens; independent valuation $0.00000145/token as of May 8, 2026.","Payment starts May 26, 2026, subject to holders setting up Datavault digital wallet and submitting opt-in agreement.","Board retains right to revoke dividend before payment date; tokens are illiquid through June 10, 2026.","Tokens are digital collectibles for personal use; no equity, dividends, or profit rights; transferability limited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95795,"accession_number":"0001193125-26-205839","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Scilex subsidiary to sell ACEA Pharma to Phoenix Asia for $1B in stock, owning 82% post-close","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["ACEA Thera sells 100% of ACEA Pharma to Phoenix Asia for 100M shares at $10/share, valued at $1B.","Post-close, ACEA Thera will own ~82% of Phoenix; Phoenix will be renamed ACEA Pharma.","Boards of all parties unanimously approved; deal expected to close by end of Q2 2026.","Closing conditions include HSR clearance, Nasdaq approval, and no material adverse effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95794,"accession_number":"0001193125-26-187620","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Scilex to pay $120M to Datavault for quantum GPU network, revenue-sharing deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront cash contribution of $120M to Datavault, payable in multiple closings by Dec 31, 2026.","Funds to deploy quantum-ready GPU infrastructure across ~100 US cities.","Datavault to pay Scilex 30% of network gross revenues until $250M, then 15% until $1.2B, then 5% thereafter.","Definitive agreement subject to negotiation, board approvals, and customary conditions; no guarantee of closing.","Binding term sheet governed by Delaware law; may be terminated by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109117,"accession_number":"0001193125-26-105675","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Scilex files federal securities fraud lawsuit over 96M misappropriated Datavault collateral shares","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed complaint in Central District of California against Marc Wade, St. James Bank, Omega & Corinth, and BNY Mellon.","Alleges unauthorized transfer and sale of ~96M Datavault shares pledged as collateral in stock loan agreement.","Seeks recovery of shares, compensatory damages >$100M, punitive damages, and disgorgement.","Claims include federal securities fraud (10b-5), state securities fraud, conversion, and negligence.","Large volume of trading allegedly impacted DVLT market price, causing substantial financial harm to Scilex."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109116,"accession_number":"0001193125-26-104940","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Scilex files federal securities fraud suit over $100M sham stock-loan; alleges defendants sold pledged shares","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Complaint filed March 11, 2026, against Marc Wade, St. James Bank, Omega & Corinth, and BNY Mellon.","Alleges 85M+ Datavault AI (DVLT) shares pledged as collateral were sold by defendants without authorization.","Loan proceeds were only ~$37M of the promised $100M, and sales were used to fund the loan and manufacture defaults.","Scilex claims BNY Mellon failed to comply with SEC reporting requirements while facilitating over $10M in suspicious trades.","Five causes of action: federal securities fraud, state securities fraud, fraudulent inducement, conversion, and negligence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109115,"accession_number":"0001193125-26-061371","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Scilex issues warrant to Oramed for 100,000 shares at $20.00 in exchange for payment deferral","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant for 100,000 shares at $20.00 issued to Oramed Pharmaceuticals for deferring an amortization payment originally due Oct 1, 2025.","Deferred payment was made in November 2025; warrant is immediately exercisable and expires Dec 13, 2029.","Exercise price subject to anti-dilution adjustments with a floor of $8.22; beneficial ownership limit set at 4.99%.","Company commits to file a resale registration statement for the underlying shares within 30 days or by March 31, 2026.","Warrant agreement includes most-favored-nations clause for six months and standard change-of-control repurchase right."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109114,"accession_number":"0001193125-26-035833","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["3.03","1.01","5.03","9.01"],"status":"ready","headline":"Scilex board revokes declared preferred stock dividend; no shares ever issued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board revoked stock dividend of 5M Series 1 Mandatory Exchangeable Preferred shares on Feb 2, 2026.","Certificate of Elimination filed Feb 3; shares revert to undesignated preferred stock.","Dividend had been postponed multiple times since October 2024 and never paid.","No shares of Series 1 Preferred were issued or outstanding at any time.","Record date and payment date set by board had been deferred indefinitely; now cancelled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109113,"accession_number":"0001193125-26-033620","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Scilex loans $20M to Q Scan, converts to shares; agrees $27.5M stock purchase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Loaned $20M to Q Scan via convertible note; note converted same day into 140.4M Q Scan common shares.","Stock Purchase Agreement to buy 193M additional Q Scan shares for ~$27.5M; closing within 5 days of Q Scan notice.","Stephen Ma, Scilex CFO, has served as interim CFO of Q Scan since Jan 16, 2026; no compensation received.","Convertible note bears 3.66% annual interest starting April 29, 2026; original maturity Oct 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125593,"accession_number":"0001193125-25-336947","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Scilex completes $27M repurchase of Penny Warrants from Oramed, eliminating dilution from 6.5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed second tranche of warrant repurchase on Dec 30, 2025 for $14M, following $13M first tranche in Sep 2025.","Total repurchase price of $27M eliminated Penny Warrants exercisable at $0.01/share for 6.5M shares of common stock.","Oramed granted optionality in Jul 2025; Scilex paid $1.5M for the option to repurchase in two tranches.","All Penny Warrants originally issued Sep 21, 2023 have now been repurchased, removing a significant dilution overhang."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125592,"accession_number":"0001193125-25-328656","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Scilex closes $22.6M first tranche of previously announced $50M non-recourse loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First tranche of $50M loan from The St. James Bank & Trust Company Ltd. closed on Dec 22, 2025.","Amount drawn: approximately $22.6 million, excluding structure fee.","Loan is non-recourse and secured by a pledge of securities per the December 1, 2025 agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125591,"accession_number":"0001193125-25-321928","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Scilex subsidiary enters $100M non-recourse loan secured by SCLX pledge","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $100M in tranches at lender's sole discretion; interest at 12-month SOFR.","Maturity 8 years from first tranche, extendable by up to 12 months; 0.25% upfront fee per tranche.","Loan secured by pledge of 70% of principal amount in SCLX common stock held by subsidiary.","Events of default include >20% stock price drop, trading volume decline, or delisting; uncured defaults increase interest by 5% and allow foreclosure.","No prepayment allowed within first 20 months except as per terms; proceeds not specified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125590,"accession_number":"0001193125-25-317587","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Scilex amends loan: principal up to $100M, collateral 85.8M Datavault shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan facility increased from $50M to $100M under amendment dated Dec 8, 2025.","Pledged collateral rises from 39.2M to 85.8M shares of Datavault AI Inc. common stock.","All other terms of the original Dec 1, 2025 Loan Agreement remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125589,"accession_number":"0001193125-25-316239","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Scilex stockholders approve repricing of stock options from $282.80 to $16.80 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved repricing of up to 289,405 options held by employees, executives, and board members.","Exercise price reduced from $282.80 to $16.80 (closing price on Dec 11, 2025).","CEO Henry Ji and CFO Stephen Ma among eligible participants; all other terms unchanged.","Vote: 3,341,659 for, 1,130,308 against, 23,971 abstain, no broker non-votes.","Repricing effective Dec 11, 2025; previously approved by Board on Oct 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125588,"accession_number":"0001193125-25-309695","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Scilex secures up to $50M non-recourse loan secured by 39.2M shares of Datavault AI (DVLT)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan of up to $50M in tranches at 12-month SOFR + 2.0% interest, maturity 4 years from first tranche.","Collateral: approx. 39.2M shares of Datavault AI (DVLT) common stock, held in securities account with lender.","Events of default include 20% decline in DVLT closing price not cured in 3 days by additional collateral, or 20% volume drop over 3 days.","Upon default, interest rate increases by 5% and lender can foreclose on pledged shares; prepayment blocked for first 20 months.","Loan is non-recourse (limited to pledged assets); upfront fee of 0.25% per tranche."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125587,"accession_number":"0001193125-25-303037","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Scilex completes $150M Bitcoin investment in Datavault AI, warrant shares now valued at $583M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Scilex purchased a pre-funded warrant for 263,914,094 Datavault shares in the second tranche, paying in Bitcoin.","Datavault stockholders approved the share issuance at their Nov 24, 2025 annual meeting.","Scilex exercised the warrant in full; shares have approximate value of $583.3M based on Nov 25 closing price of $2.21.","Both companies plan to collaborate on Real World Asset tokenization in 2026.","The aggregate purchase price for both tranches was $150M in Bitcoin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125586,"accession_number":"0001193125-25-293861","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Scilex receives $20.4M from Armistice warrant exercise; issues new warrants for 1.36M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrants (904,396 shares) exercised at reduced price $22.51/share, gross proceeds $20.36M.","New unregistered warrants issued for 1,356,594 shares at $29.00 strike, 5-year term.","Placement agents to receive 8% cash fee and warrants for 72,352 shares.","Company to file resale registration statement for new warrant shares within 45 days.","Investor previously held warrants with exercise prices of $38.50 and $22.72."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125585,"accession_number":"0001193125-25-264143","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Scilex in-licenses Datavault AI tech for biotech asset tokenization; $10M upfront, $2.55B milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Worldwide exclusive license from Datavault AI for tokenizing genomic, DNA, diagnostic, therapeutic data in biotech/pharma.","Non-refundable upfront fee $10M payable in four equal $2.5M quarterly installments starting Dec 31, 2025.","Potential sales milestone payments up to $2.55B and 5% royalty on net sales; minimum annual royalty $1M after 24 months.","Core patent includes 'Platform and Method for Tokenizing DNA Data' (U.S. Pat. App. 17/941,623) plus suite of issued/pending patents.","Scilex aims to create a Biotech Exchange platform for secure tokenization, trading, and monetization of biotech assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125584,"accession_number":"0001193125-25-259819","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Scilex terminates ELOC with Tumim; to pay $2.7M cash instead of issuing 150k shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scilex and Tumim Stone Capital terminated their July 22, 2025 ELOC agreement.","In lieu of 150,000 commitment shares, Scilex will pay Tumim $2.7M in three installments: $500k by Oct 31, $500k by Nov 14, $1.7M by Dec 15, 2025.","Termination effective upon full payment; if not paid by Dec 15, commitment shares must be issued.","Company says termination due to no longer needing additional capital under the ELOC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125583,"accession_number":"0001193125-25-233450","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Scilex appoints Stephen Ma as COO; he continues as CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Ma, 53, appointed COO effective Oct 1, 2025; retains CFO, SVP, Corporate Secretary, and Board roles.","Ma has 15+ years finance/operations experience in pharma and venture-backed biotech.","Also appointed CFO of Semnur Pharmaceuticals (OTC:SMNR) on Sep 22, 2025.","No change in compensation for his COO appointment; standard indemnification agreement in place."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125582,"accession_number":"0001193125-25-226992","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Scilex enters warrant exercise agreement for $2.7M proceeds; issues new warrants for 275K shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrant holders exercise 179,236 shares at net $15.00/share after $7.72 deferral fee, raising ~$2.7M.","Company will use $2.5M of proceeds to repay outstanding Tranche B Notes (senior secured convertible notes).","New September 2025 warrants issued: 275,000 shares at $20 strike, expiring Dec 13, 2029, immediately exercisable.","Holders defer Oct 1, 2025 amortization payment to Jan 1, 2026 in exchange for $7.72/share deferral fee.","Placement agents are Rodman & Renshaw and Stockblock Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142326,"accession_number":"0001193125-25-220481","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Scilex closes $150M Bitcoin investment in Datavault AI; receives 15M shares and pre-funded warrant for 263.9M more","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Scilex invested $150M in Bitcoin for Datavault AI (DVLT) shares and warrants at $0.5378 per share effective price.","Initial closing delivered 15M Datavault shares; second tranche of pre-funded warrant for 263,914,094 shares awaits stockholder approval.","Scilex gets board nomination rights: two directors if ownership ≥10%, one director if 5-10%.","Datavault management unchanged; proceeds intended to accelerate supercomputing and AI infrastructure.","Deal priced using Bitcoin spot rate from Coinbase; Datavault shares offered under effective S-3 shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142325,"accession_number":"0001193125-25-220446","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","2.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Scilex sells 12.5M Semnur shares for $200M Bitcoin; closes Sept 23, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scilex sold 12,500,000 Semnur common shares at $16.00/share to Biconomy for $200M in Bitcoin.","Bitcoin payment valued at Coinbase spot rate; closing occurred on September 23, 2025.","Semnur must file a resale registration statement within 90 days of closing.","Scilex engaged Biconomy for cryptocurrency treasury management; proceeds to fund Bitcoin purchases.","Company filed supplemental risk factors on Bitcoin volatility, regulatory and accounting risks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142324,"accession_number":"0001193125-25-220435","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Scilex directors Navani and Shah resign; CFO Ma joins board; consulting pact with Shah affiliate","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annu Navani and Jaisim Shah resigned as directors on Sept 22, 2025, in connection with the Semnur business combination.","Board size decreased from 6 to 5; CFO Stephen Ma appointed to fill the vacancy effective immediately.","Scilex entered a 5-year consulting agreement with Inform LLC (Shaffiliate) for $50,000/month; Shah continues vesting in stock options.","Resignations were not due to disagreement with the company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142323,"accession_number":"0001193125-25-184619","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Scilex CEO Jaisim Shah resigns to focus on Semnur; Henry Ji appointed CEO; Semnur gets $20M PIPE","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jaisim Shah resigned as CEO/President of Scilex effective Aug 17, 2025; remains on Board and will focus full time on Semnur.","Henry Ji, previously Executive Chairman, appointed as Scilex's new CEO and President effective immediately.","Semnur (majority-owned subsidiary) entered a $20M private placement at $16/share; proceeds fund SP-102 Phase 3 trial.","The PIPE is contingent on Semnur's business combination with Denali Capital Acquisition Corp.","Jaisim Shah's departure is to dedicate full attention to advancing SP-102 for LRP/Sciatica toward regulatory approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142322,"accession_number":"0001193125-25-162969","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Scilex subsidiary Semnur amends Denali merger deal to allow additional share issuances pre-closing","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment modifies Exchange Ratio and Merger Consideration definitions to account for shares issued after signing date (PIPE/Advisor Shares).","Exchange Ratio stays 1.25-to-1, but denominator now includes post-signing issuances, increasing total shares exchanged.","Merger Consideration recalculated: $2.5B plus (post-signing shares * 1.25 * $10.00), divided by $10.00.","Authorized capital updated to 785M shares (740M common, 45M preferred) immediately before closing.","Deal allows potential PIPE financing and advisor share issuance before closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142321,"accession_number":"0001193125-25-162938","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Scilex enters $100M equity line, exchanges warrants, gets option to repurchase Penny Warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity line with Tumim Stone Capital: up to $100M common stock at 96-97% of lowest VWAP; 150k commitment shares.","Exchange of existing Tranche B warrants (107,142 shares, $36.40 strike) for new warrants (500,000 shares, $40 strike; exp. Oct 2029).","Option to repurchase 6.5M Penny Warrants from Oramed for $27M, plus $1.5M option fee; extends Oramed note maturity to March 2026.","Warrant repurchase contingent on payments by Sep 30 and Dec 31, 2025; full exercise removes make-whole payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160353,"accession_number":"0000950170-25-089059","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Scilex defers record date for preferred stock dividend to future date determined by Board","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Record date shifted from May 2, 2025 to a later date to be set by the Board.","Dividend consists of Series 1 Mandatory Exchangeable Preferred Stock exchangeable for up to 10% of Scilex's interest in Semnur Pharmaceuticals.","Board retains the right to further change any New Record Date or revoke the Dividend entirely.","Deferral based on Board's assessment of solvency and surplus conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160352,"accession_number":"0000950170-25-088971","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Scilex stockholder meeting elects Shah and Ji as directors, ratifies BPM auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jaisim Shah elected with 3,537,589 votes for; Henry Ji with 3,433,624 votes for.","Ratification of BPM LLP as independent auditor: 5,354,958 for, 166,743 against, 78,928 abstentions.","Common stock turnout ~67.3% (4,678,182 shares); Series A preferred 100% represented (29,057,097 shares).","Broker non-votes on director election: 1,739,837 for both nominees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160351,"accession_number":"0000950170-25-081638","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Scilex annual meeting adjourned due to lack of quorum; reconvenes June 20","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting convened and adjourned on June 4, 2025, without conducting business due to insufficient quorum.","Meeting will reconvene on June 20, 2025 at 9:00 a.m. PT via virtual webcast to allow more time for voting.","No changes to proposals from definitive proxy statement filed May 16, 2025; record date remains May 15, 2025.","Proxies previously submitted will be voted unless revoked; stockholders who already voted need not take action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160350,"accession_number":"0000950170-25-068621","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Scilex adjusts non-employee director equity grants post 1-for-35 reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial option grant reduced from 250,000 to 7,142 shares per new director.","Annual option grant for continuing directors reduced from 100,000 to 2,857 shares.","Cash compensation unchanged: Board $82,500, committee chairs $37,500, other members $15,000.","Policy effective retroactively to April 15, 2025.","Share numbers subject to adjustment for future splits, dividends, etc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160349,"accession_number":"0000950170-25-061130","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Scilex regains Nasdaq minimum bid price compliance as of April 30, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Scilex on April 30, 2025 that compliance with Rule 5550(a)(2) was regained.","Closing bid price stayed at or above $1.00 for ten consecutive trading days (April 15–29).","Common stock (SCLX) and warrants (SCLXW) continue trading normally on Nasdaq.","No changes to business operations or financial guidance were announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160348,"accession_number":"0000950170-25-056497","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Scilex changes dividend record date to May 2, 2025 for preferred stock exchangeable into up to 10% of Semnur","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of Series 1 Mandatory Exchangeable Preferred Stock (exchangeable for up to 10% of Semnur Pharmaceuticals stake) record date moved from April 11 to May 2, 2025.","Payment date to be set by Board within 60 days after new record date (no later than July 1, 2025).","Board retains right to further change the record date or revoke the dividend prior to payment, including based on solvency analysis changes.","Dividend apportioned pro rata among stockholders and certain other securityholders as of the new record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160347,"accession_number":"0000950170-25-056022","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Scilex sub Semnur amends SPAC merger agreement after Denali Nasdaq delisting; outside date extended to Sept 30, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment dated April 16, 2025 modifies covenants to address Denali's de-listing from Nasdaq and subsequent quotation on OTC Markets.","Denali must amend organizational documents to extend business combination deadline to December 11, 2025.","Outside date for merger completion extended to September 30, 2025, or later if an extension amendment is in effect.","Denali to use reasonable best efforts to list Parent Units, Class A Shares and Parent Warrants on OTC Markets after delisting.","Merger agreement otherwise unchanged; Semnur remains wholly owned subsidiary of Scilex until closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160346,"accession_number":"0001193125-25-080856","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Scilex Holdings files 1-for-35 reverse stock split to regain Nasdaq compliance effective April 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board set ratio at 1-for-35 on April 3, 2025; stockholders approved March 19, 2025.","Reverse split effective 12:01 a.m. ET April 15, 2025; common stock to trade adjusted on Nasdaq.","No fractional shares; cash in lieu based on closing price on April 14, 2025.","Warrants adjusted: every 35 warrants now exercisable for 1 share at $402.50 (35x$11.50).","Trading symbol SCLX unchanged; new CUSIP 80880W205."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160345,"accession_number":"0001193125-25-078604","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Scilex announces 1-for-35 reverse stock split effective April 15, 2025 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ratio of 1-for-35; effective 12:01 a.m. ET on April 15, 2025.","Outstanding shares reduced from approx. 243M to approx. 6.9M.","Stockholders approved split at March 19 special meeting; board set ratio on April 3.","No fractional shares; cash payment in lieu based on April 14 closing price.","Reverse split applies to warrants, preferred stock, convertible notes, and options with proportionate adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178633,"accession_number":"0000950170-25-042708","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Scilex shareholders approve reverse stock split within 1:14 to 1:50 range","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split of common stock at ratio between 1:14 and 1:50; board to set final ratio by March 19, 2026.","Proposal received 151.1M votes for, 49.2M against, 1.6M abstentions, representing ~75% approval of votes cast.","Adjournment proposal also passed (151.8M for, 47.3M against) but was not necessary.","All 29.1M Series A preferred shares, voting on as-converted basis, were represented and voted in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178632,"accession_number":"0000950170-25-035963","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Scilex changes record date for preferred stock dividend from Jan 28 to Apr 11, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["New record date for Dividend of Series 1 Mandatory Exchangeable Preferred Stock is April 11, 2025 (previously Jan 28).","Payment date to be within 60 days after new record date, no later than June 10, 2025.","Dividend exchangeable for up to 10% of Scilex's ownership in wholly owned subsidiary Semnur Pharmaceuticals.","Payment conditioned on Board not revoking dividend prior to Payment Date, including solvency analysis.","Board retains right to further change record date at any time before actual payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178631,"accession_number":"0001193125-25-043879","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Scilex voluntarily terminates ATM equity offering agreement with sales agents","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales Agreement with B. Riley, Cantor Fitzgerald, and H.C. Wainwright terminated effective March 5, 2025; no penalty incurred.","During the program, Scilex sold 2,764,187 shares for aggregate gross proceeds of approximately $2,693,840.","The at-will termination suggests the company may not require further equity ATM financing or is pursuing alternative capital sources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178630,"accession_number":"0001193125-25-043338","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Scilex sells 4% royalty on Gloperba/Elyxyb to defer Tranche B amortization to 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 4% of aggregate net sales of Gloperba and Elyxyb to Oramed, Murchinson, and 3i; consideration is deferral of First Amortization Payment on Tranche B Notes to Oct 8, 2026.","Entered Security Agreement granting first-priority liens on royalty collateral; Note Agent's lien subordinated to second priority.","Licensed exclusive worldwide ex-US rights to Gloperba to RoyaltyVest Ltd on 50/50 net revenue split.","Amended ZTlido Royalty Agreement to allow asset sale without consent if all Debt Instrument obligations are paid in full.","Transaction closed Feb 28, 2025; grants Royalty and Exclusive Rights under January 2, 2025 Tranche B Consents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178629,"accession_number":"0001193125-25-039211","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Scilex licenses ZTlido and SP-103 to RoyaltyVest for ex-US markets; 50% net revenue share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Licensed ZTlido (lidocaine topical system 1.8%) and SP-103 for commercialization outside US; Licensor retains US and stated territories.","RoyaltyVest pays Scilex Pharma 50% of net revenue from ex-US sales; annual $200K commitment until first regulatory approval.","Licensee must use commercially reasonable efforts to obtain regulatory approval in at least one Major Market Country within 18 months.","Scilex Pharma grants exclusive, non-transferable license; Scilex Holding Company provides parent guarantee for performance.","Agreement effective February 22, 2025, replacing the October 2024 Rest of World License Term Sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178628,"accession_number":"0001193125-25-009911","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Scilex extends Oramed note maturity to Dec 2025; issues 3.25M shares as consideration","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity date of Oramed Senior Secured Promissory Note extended from March 21, 2025 to December 31, 2025.","SCLX Stock Acquisition JV to deliver 3,250,000 shares of Scilex common stock to Oramed as consideration.","New covenant prohibits increasing compensation or granting additional equity awards to officers/directors while note outstanding.","Cash sweep definition amended; Oramed may redirect prepayments to Tranche B Notes in lieu of principal on Oramed Note.","The extension provides additional time to repay the Oramed Note and aligns with other debt arrangements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178627,"accession_number":"0000950170-25-007359","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Scilex regains Nasdaq compliance by filing overdue Q3 2024 10-Q","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed Form 10-Q for quarter ended Sept 30, 2024 on Jan 17, 2025, curing late filing.","Received Nasdaq notice Jan 21, 2025 confirming compliance with Listing Rule 5250(c)(1).","Earlier delinquency stemmed from failure to timely file Q3 10-Q, risking delisting.","No financial results released; compliance removal is a procedural milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178626,"accession_number":"0001193125-25-000984","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Scilex defers $6.25M amortization payment, issues 5M shares to noteholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered deferral letters with Tranche B noteholders; first $6.25M amortization due Jan 2 deferred to Jan 31, then to Oct 8, 2026.","Delivered 5M common shares to noteholders: Oramed 2.5M, BPY 720k, Nomis 1.28M, 3i LP 500k.","Paid $1.11M toward amortization and make-whole interest to achieve further deferral to Oct 8, 2026.","Term sheet provides for 4% royalty on worldwide net sales of Gloperba and Elyxyb (ex-Canada) for 10 years.","Company seeking to extend Oramed promissory note maturity from March 21, 2025 to Dec 31, 2025; not yet agreed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195296,"accession_number":"0001193125-24-286244","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Scilex moves preferred stock dividend record date to Jan 28, 2025; payment by Mar 29","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Record date changed from Nov 7, 2024 to Jan 28, 2025 for Series 1 Mandatory Exchangeable Preferred Stock dividend.","Dividend exchangeable for up to 10% of Scilex's ownership in wholly owned subsidiary Semnur Pharmaceuticals.","Payment date to be set by Board within 60 days of record date (no later than Mar 29, 2025).","Board retains right to further change record date or revoke dividend before payment, including for solvency concerns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195295,"accession_number":"0001193125-24-278311","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Scilex raises $17M in registered direct offering, plus $1M warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$17M from sale of 26.355M shares, pre-funded warrants, and 57.513M common warrants.","Combined offering price $0.59 per share/warrant unit; common warrants at $0.649/share.","Separate warrant amendment yields ~$1.041M from exercise of 1.764M shares at $0.59.","Net proceeds for working capital, R&D, commercialization, and possible debt repayment.","Common warrants exercisable in 6 months; half expire in 2.5 yrs, half in 5 yrs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195294,"accession_number":"0001193125-24-273896","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Scilex obtains consent to sell up to 60M shares to fund debt payments due Dec 2024 and Jan 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Consented to sell up to 60,068,585 Scilex shares held by SCLX JV to raise cash for Note payments.","First $13.24M of proceeds to cover Tranche A Note principal due Dec 21, 2024.","Next proceeds to cover Tranche B Note amortization due Jan 2, 2025, then remaining Tranche A balance.","Oramed and Tranche B noteholders granted limited waiver of defaults if payments made from proceeds.","Sales commission capped at 2.5% of gross proceeds to designated broker."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195293,"accession_number":"0000950170-24-134767","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Scilex forms JV to develop Phase 2 oral KDS2010 for obesity and Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scilex contributes $50M of Semnur stock for controlling stake in Scilex Bio JV; IPMC holds 40%.","NeuroBiogen grants Scilex Bio exclusive worldwide license to KDS2010 for all indications.","KDS2010 is a reversible MAO-B inhibitor; Phase 1 shows favorable safety; Phase 2 ongoing in obesity and Alzheimer's.","Obesity drug market forecast ~$150B by early 2030s; Alzheimer's market >$15B by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195292,"accession_number":"0000950170-24-133869","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Scilex appoints BPM LLP as new independent auditor effective for Q3 2024 and FY 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee approved BPM LLP as independent registered public accounting firm on Dec 5, 2024, effective immediately.","BPM will audit financial statements for Q3 2024 and fiscal year ending Dec 31, 2024.","No prior consultation with BPM on accounting principles; no disagreements or reportable events with predecessor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195291,"accession_number":"0001193125-24-268137","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"David Lemus resigns from Scilex Holding Board of Directors effective Nov 27, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Lemus resigned from the Board and all committees, effective November 27, 2024.","Resignation cited personal and professional reasons; no successor has been named.","Lemus also stepped down from any officer or director roles at Scilex subsidiaries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195290,"accession_number":"0001193125-24-264187","cik":1820190,"company_name":"Scilex Holding Co","ticker":"SCLX","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Scilex obtains waivers for late Q3 filing; must file by Jan 20 or face default","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Waivers from Oramed and Tranche B holders waive defaults from failure to timely file Q3 10-Q.","Q3 10-Q due no later than January 20, 2025; new independent auditor must be engaged.","Remaining principal on Oramed Note ~$37M; Tranche B Notes ~$41M after conversions.","Failure to meet deadline triggers immediate event of default, acceleration, and penalties.","Risk factor update warns of potential Nasdaq delisting and inability to raise capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":57825524.93676813,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-11-22T23:59:59+00:00|195290"}